#ASCT

@hemehub.bsky.social

3 weeks ago

🩸Facts about Multiple Myeloma:

Frontline Integration

#MultipleMyeloma #Hematology #BispecificAntibodies #StemCellTransplant #ASCT #BsAbs #MRD #ClinicalTrials #Elranatamab #Teclistamab #MajesTEC4 #MajesTEC5 #HemOnc #HEMEHUB

0 0 0 0

@hemehub.bsky.social

1 month ago

🩸 Today’s question focuses on post-ASCT maintenance therapy.

See the answer and explanation on the next slide!

#MultipleMyeloma #ASCT #StemCellTransplant #NKCellActivity #Hematology #HemeOnc #Cancer #MedEd

1 0 0 0

@hemehub.bsky.social

1 month ago

🩸🔬Today's question!

See the answer and explanation on the next slide.

#MultipleMyeloma #NDMM #AutologousStemCellTransplant #ASCT #VRd #GMMGHD7 #MRDNegativity #ClinicalTrials #Hematology #HemOnc #MedEd

0 0 0 0

CancerCop

@cancercop.bsky.social

7 months ago

Day +24 Post transplant.
Since discharge, this will be my 2nd stay in hospital.
Apparently I’m more ill than I feel and so blood tests, blood cultures, xray, ct scan, 3 different swabs and high strength antibiotics, iv paracetamol and loads of fluids.
Well, today’s been fun.
#Allo #ASCT

0 0 0 0

Aurino Jr

@aurino.bsky.social

8 months ago

Transição para uma Economia de Baixo Carbono YouTube video by Associação dos Servidores do MCTI

Transição para uma Economia de Baixo Carbono www.youtube.com/watch?v=rtlZ....
Foi em 26/06/25 via #ASCT - #MCTI www.instagram.com/p/DLS2xIky4I6/.

5ª CNCTI - Planeta Água: Cultura oceânica para enfrentar as mudanças climáticas no meu território www.gov.br/mcti/pt-br/a.... 07 a 12/10 e 20 a 26/10/25.

1 1 1 0

SUD-Rail Centre Val de Loire

@sudrailcvdl.bsky.social

8 months ago

Les #ASCT n’ont pas oubliés les VAO !!! Qu’ils et elles restent près de leur téléphone, la #direction #SNCF risque d’en avoir besoin…

1 0 0 0

ECOG-ACRIN Cancer Research Group

@eaonc.bsky.social

1 year ago

Now Enrolling: EA4232 for Patients With Peripheral T-Cell Lymphoma This is the first randomized phase 3 study to evaluate autologous stem cell transplantation in patients with this rare and aggressive form of non-Hodgkin lymphoma

Trial Activation: EA4232, led by Nora Bennani, MD of @mayoclinic.org, is a randomized phase 3 study to evaluate benefits of #ASCT in patients with #PeripheralTCellLymphoma that achieved a first complete remission (CR1) following induction therapy (PTCL-STAT) bit.ly/EA4232-blog

2 2 0 0